TD Asset Management Inc Acquires 4,637 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

TD Asset Management Inc increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 240,358 shares of the company’s stock after purchasing an additional 4,637 shares during the period. TD Asset Management Inc’s holdings in Teva Pharmaceutical Industries were worth $4,028,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $39,000. New Age Alpha Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $43,000. Sound Income Strategies LLC raised its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after buying an additional 2,824 shares during the last quarter. Banque Cantonale Vaudoise purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter worth $74,000. Finally, Brooklyn Investment Group raised its holdings in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after buying an additional 4,014 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.6%

Shares of Teva Pharmaceutical Industries stock opened at $19.43 on Tuesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm has a fifty day moving average price of $18.95 and a 200 day moving average price of $17.17. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The stock has a market cap of $22.28 billion, a PE ratio of -121.41, a price-to-earnings-growth ratio of 1.06 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. During the same quarter last year, the company posted $0.61 earnings per share. The firm’s revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on TEVA. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus price target of $25.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.